Industry
Biotechnology
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
May 24, 2024 | 3:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 24, 2024 | 2:56 pm
Portfolio Pulse from Vandana Singh
May 23, 2024 | 4:53 pm
Portfolio Pulse from Benzinga Newsdesk
May 23, 2024 | 4:35 pm
Portfolio Pulse from Benzinga Insights
May 23, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 23, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
May 23, 2024 | 11:01 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 11:36 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 11:35 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.